Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial.
Fiche du document
2011
- doi: 10.1097/NMD.0b013e3182125d19
- issn: 0022-3018
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1097/NMD.0b013e3182125d19
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/21451348
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1539-736X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3F4B4B6BB76E7
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
U. Kramer et al., « Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. », Serveur académique Lausannois, ID : 10.1097/NMD.0b013e3182125d19
Métriques
Partage / Export
Résumé
Motive-oriented therapeutic relationship (MOTR, also called complementary therapeutic relationship) was postulated to be a particularly helpful therapeutic ingredient in the early-phase treatment of patients with personality disorders, in particular borderline personality disorder (BPD). The present pilot study of randomized controlled trial using an add-on design aims to investigate the effects of MOTR in early-phase treatment (up to session 10), with BPD patients on therapeutic alliance, session impact, and outcome. In total, N = 25 patients participated in the study. BPD patients were randomly allocated to a manual-based investigation process in 10 sessions or to the same investigation process infused with MOTR. Adherence ratings were performed and yielded satisfactory results. The results suggested a specific effectiveness of MOTR on the interpersonal problem area, on the quality of the therapeutic alliance and the quality of the therapeutic relationship, as rated by the patient. These results may have important clinical implications for the early-phase treatment of patients presenting with BPD.